Drug Use in Systemic Lupus Erythematosus (SLE) Outpatients

DOI

10.2991/ahsr.k.210115.090How to use a DOI?

Keywords

SLE, drug use, outpatients, disease duration

Abstract

The Systemic Lupus Erythematosus (SLE) is an autoimmune disease, affecting most of the patients’ organ systems. The disease is considered to be a chronic disease and its effect makes unpredictable flares. According to Yayasan Lupus Indonesia (YLI), in this decade, the total amount of SLE patients is increasing. Drug use evaluation in SLE patients is needed to improve the treatment so that the patient gets the optimal outcome. The overall aim of this research is to determine the drugs given for patients with SLE and also to know the characteristics of patients with SLE. This was a descriptive study, non-experimental research, conducted from April to August 2017. The subjects had already been diagnosed with SLE for more than 3 months. Two hundred and twenty-two patients fulfilled the inclusion criteria. Most of them (98.20%) were women, on a productive age. Only 7.66 % of the patients were given no immunosuppressant. The most used was a combination of 19.82% of methylprednisolone and mycophenolate mofetil. To reduce the side effect of the prolonged use of corticosteroid drugs, 55.41% was given Calcium supplements and Vitamin D, and 30.18% was given anti-nausea and vomiting. The average number of drugs given was six. The most drug use in SLE outpatients was corticosteroids and the physicians had already combined the therapy with Calcium, Vitamin D, antinausea vomiting to reduce its side effect. There was no correlation between age and disease duration with the total drug given to the SLE outpatients (p 0.14 and 0.60).

Copyright

© 2021, the Authors. Published by Atlantis Press.

Open Access

This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

TY  - CONF
AU  - Maria Caecilia N. Setiawati
AU  - Ika Puspitaningrum
AU  - Nyoman Kertia
PY  - 2021
DA  - 2021/01/16
TI  - Drug Use in Systemic Lupus Erythematosus (SLE) Outpatients
BT  - Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020)
PB  - Atlantis Press
SP  - 451
EP  - 455
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.210115.090
DO  - 10.2991/ahsr.k.210115.090
ID  - Setiawati2021
ER  -